Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 216-133-4 | CAS number: 1506-02-1
Carcinogenicity
Administrative data
Description of key information
The mutagenicity studies and the oral rat study on liver tumour initiating and promoting activity were used to assess the carcinogenicity of AHTN. The result is that AHTN has no carcinogenic potential.
AHTN is demonstrated to be not genotoxic. There are no indications from repeated dose toxicity studies, which could be used to judge the carcinogenic potential. It has been shown that AHTN has no liver tumour initiating and promoting activity in rats exposed to human-relevant doses.
Key value for chemical safety assessment
Carcinogenicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Carcinogenicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Carcinogenicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
Based on the available information classification for carcinogenicity is not warranted in accordance with EU Classification, Labelling and Packaging of Substances and Mixtures (CLP) Regulation No. 1272/2008.
Additional information
ATHN has been tested for liver tumour initiating and promotingactivity in rats exposed to human-relevant doses. Female and male juvenile Wistar rats (5 weeks old at start) were exposed to AHTN (300μg/kg bw day) dissolved in isopropylmyristate alone or to single intraperitoneal dose of diethylnitrosamine (DEN) (100 mg/kg bw day) for 90 days.
After the exposure period, the liver was removed and examined by light microscopy. An immunohistochemical analysis was performed. The presence of placental glutathione Stransferase (GST-P)-positive hepatic lesions was also assessed.
Male animals exposed to AHTN either alone or in combination with DEN showed a similar number of GST-P-positive single hepatocytes compared to the control group. GST-P-positive mini-foci and foci were not observed.
In female rats there was no difference in the number of GST-P-positive single hepatocytes and mini-foci between the AHTN-exposed rats and the untreated animals.
The female rats that were exposed to AHTN either alone or in combination with DEN, GST-P-positive foci could not be observed or appeared to be similar in number to that in untreated rats.
It can be concluded that under the conditions in this study, AHTN lacks initiaton and promotion of liver tumor and it does not lead to hepatotoxicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
